Weekly Investment Analysts’ Ratings Updates for Boston Scientific (BSX)

Boston Scientific (NYSE: BSX) has recently received a number of price target changes and ratings updates:

• 7/15/2026 – Boston Scientific had its price target lowered by Mizuho from $90.00 to $70.00. They now have an “outperform” rating on the stock.
• 7/13/2026 – Boston Scientific had its price target lowered by Royal Bank Of Canada from $100.00 to $85.00. They now have an “outperform” rating on the stock.
• 7/8/2026 – Boston Scientific had its price target lowered by Needham & Company LLC from $77.00 to $57.00. They now have a “buy” rating on the stock.
• 7/7/2026 – Boston Scientific was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 7/6/2026 – Boston Scientific was given a new $65.00 price target by Evercore Inc.
• 6/25/2026 – Boston Scientific had its price target lowered by Stifel Nicolaus from $75.00 to $65.00. They now have a “buy” rating on the stock.
• 6/24/2026 – Boston Scientific had its price target lowered by Jefferies Financial Group Inc. from $100.00 to $67.00. They now have a “buy” rating on the stock.
• 6/16/2026 – Boston Scientific had its “buy” rating reaffirmed by BTIG Research. They now have a $65.00 price target on the stock.
• 6/12/2026 – Boston Scientific had its “overweight” rating reaffirmed by Piper Sandler. They now have a $65.00 price target on the stock.
• 6/5/2026 – Boston Scientific was downgraded by Zacks Research from “hold” to “strong sell”.
• 6/4/2026 – Boston Scientific had its price target lowered by Truist Financial Corporation from $85.00 to $64.00. They now have a “buy” rating on the stock.
• 6/2/2026 – Boston Scientific had its price target lowered by BTIG Research from $80.00 to $65.00. They now have a “buy” rating on the stock.
• 6/1/2026 – Boston Scientific had its price target lowered by Canaccord Genuity Group Inc. from $71.00 to $70.00. They now have a “buy” rating on the stock.
• 5/29/2026 – Boston Scientific was downgraded by Wolfe Research from “outperform” to “peer perform”.
• 5/28/2026 – Boston Scientific had its “outperform” rating reaffirmed by Royal Bank Of Canada.
• 5/28/2026 – Boston Scientific was given a new $71.00 price target by The Goldman Sachs Group, Inc..
• 5/28/2026 – Boston Scientific had its price target lowered by Citigroup Inc. from $87.00 to $70.00. They now have a “buy” rating on the stock.
• 5/28/2026 – Boston Scientific was given a new $70.00 price target by Robert W. Baird.
• 5/28/2026 – Boston Scientific had its price target lowered by Leerink Partners from $87.00 to $74.00. They now have an “outperform” rating on the stock.
• 5/28/2026 – Boston Scientific had its price target lowered by Barclays PLC from $96.00 to $89.00. They now have an “overweight” rating on the stock.
• 5/28/2026 – Boston Scientific had its “equal weight” rating reaffirmed by Wells Fargo & Company. They now have a $55.00 price target on the stock, down from $75.00.
• 5/28/2026 – Boston Scientific was downgraded by Wells Fargo & Company from “overweight” to “equal weight”. They now have a $55.00 price target on the stock, down from $75.00.
• 5/27/2026 – Boston Scientific was given a new $75.00 price target by Stifel Nicolaus.
• 5/19/2026 – Boston Scientific had its price target lowered by Robert W. Baird from $78.00 to $75.00. They now have an “outperform” rating on the stock.
• 5/18/2026 – Boston Scientific had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $77.00 price target on the stock.
• 5/18/2026 – Boston Scientific had its price target lowered by Bank of America Corporation from $105.00 to $68.00. They now have a “buy” rating on the stock.
• 5/18/2026 – Boston Scientific had its “buy” rating reaffirmed by BTIG Research. They now have a $80.00 price target on the stock.

Insider Buying and Selling

In related news, Director Edward J. Ludwig acquired 3,580 shares of the stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average cost of $56.68 per share, with a total value of $202,914.40. Following the completion of the purchase, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. This trade represents a 16.44% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Cheryl Pegus bought 1,770 shares of the company’s stock in a transaction dated Wednesday, May 20th. The stock was bought at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the acquisition, the director directly owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired 9,800 shares of company stock worth $554,012 in the last quarter. Insiders own 0.34% of the company’s stock.

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.